Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Payables: 2020-2025

Historic Payables for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Sep 2025 value amounting to $8.0 million.

  • Maravai Lifesciences Holdings' Payables fell 15.76% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.0 million, marking a year-over-year increase of 0.05%. This contributed to the annual value of $12.0 million for FY2024, which is 11.45% up from last year.
  • Latest data reveals that Maravai Lifesciences Holdings reported Payables of $8.0 million as of Q3 2025, which was down 30.60% from $11.5 million recorded in Q2 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Payables peaked at $718.2 million during Q4 2022, and registered a low of $4.8 million during Q1 2023.
  • For the 3-year period, Maravai Lifesciences Holdings' Payables averaged around $131.1 million, with its median value being $10.7 million (2023).
  • Per our database at Business Quant, Maravai Lifesciences Holdings' Payables spiked by 8,707.95% in 2022 and then plummeted by 98.60% in 2024.
  • Over the past 5 years, Maravai Lifesciences Holdings' Payables (Quarterly) stood at $8.2 million in 2021, then surged by 8,707.95% to $718.2 million in 2022, then crashed by 98.51% to $10.7 million in 2023, then rose by 11.45% to $12.0 million in 2024, then dropped by 15.76% to $8.0 million in 2025.
  • Its last three reported values are $8.0 million in Q3 2025, $11.5 million for Q2 2025, and $9.5 million during Q1 2025.